Wei Luo, MD, PhD

Translational Research Scientist
Pharmacology and Therapeutics
Roswell Park
Special Interests: 
Anti-tumor activity of vitamin D
Vitamin D signaling pathway and metabolism in cancer
Mechanisms of vitamin D anti-tumor activity
Small molecular inhibitors of vitamin D catabolic enzyme CYP24A1
Anti-cancer drug discovery


Our work focuses on vitamin D in prevention and treatment of malignant diseases. Currently, we are interested in understanding molecular mechanisms affecting vitamin D anti-tumor activity. Specifically, we seek to understand the effect of onco-protein kinases on vitamin D signaling. We found that protein kinases CK2 and PIM1 regulate the expression of CYP24A1, a major enzyme responsible for inactivating vitamin D. We are developing strategies to inhibit the expression and/or activity of CYP24A1 thereby then enhancing the vitamin D anti-tumor action. We seek to understand the interaction between p53 and vitamin D in cancer since vitamin D demonstrates differential effect in p53 mutant vs p53 wild cancer cells. Using cell-based luciferase report assay, we are screening to discover small molecules for improving vitamin D anti-tumor action.


Education and Training: 
PhD - Shanghai Second Medical University, Shanghai, China
MD - Shanghai Second Medical University, Shanghai, China
Professional Memberships: 
American Association for Cancer Research (AACR)
Professional Experience: 
2007-Present - Translational Research Scientist - Department of Pharmacology and Therapeutics - Roswell Park Cancer Institute, Buffalo, NY